Literature DB >> 18305567

PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells.

Nadya al Yacoub1, Malgorzata Romanowska, Sybille Krauss, Susann Schweiger, John Foerster.   

Abstract

Peroxisome proliferator-activated receptor beta/delta (PPARdelta) is a nuclear hormone receptor regulating diverse biological processes, including beta-oxidation of fatty acid and epithelial cell differentiation. To date, the role of PPARdelta in the immune system has not been thoroughly studied. Here, we show that PPARdelta is expressed in activated human T cells purified from peripheral blood as well as in T cells isolated from affected psoriasis skin lesions. PPARdelta is induced in T cells on stimulation with type 1 IFN. Functionally, PPARdelta enhances proliferation of primary T cells and blocks apoptosis induced by type 1 IFN and by serum deprivation. We show that these cellular functions are mediated by the activation of extracellular signal-regulated kinase1/2 signaling. Our results (1) establish a direct molecular link between type 1 IFN signaling and PPARdelta, (2) define a functional role for PPARdelta in human T cells, and (3) suggest that the induction of PPARdelta by type 1 IFN contributes to the persistence of activated T cells in psoriasis skin lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305567     DOI: 10.1038/jid.2008.32

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  14 in total

Review 1.  Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.

Authors:  S Balachandar; A Katyal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-09       Impact factor: 3.267

2.  PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.

Authors:  Y-J Li; L Sun; Y Shi; G Wang; X Wang; S E Dunn; C Iorio; R A Screaton; D E Spaner
Journal:  Leukemia       Date:  2017-01-04       Impact factor: 11.528

Review 3.  A cutting edge overview: psoriatic disease.

Authors:  Siba P Raychaudhuri
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 4.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

5.  Research resource: Comparative nuclear receptor atlas: basal and activated peritoneal B-1 and B-2 cells.

Authors:  Cody J Diehl; Grant D Barish; Michael Downes; Meng-Yun Chou; Sven Heinz; Christopher K Glass; Ronald M Evans; Joseph L Witztum
Journal:  Mol Endocrinol       Date:  2011-01-27

6.  Reduced expression of peroxisome proliferator-activated receptor alpha in BAL and blood T cells of non-löfgren's sarcoidosis patients.

Authors:  Muntasir Abo Al Hayja; Anders Eklund; Johan Grunewald; Jan Wahlström
Journal:  J Inflamm (Lond)       Date:  2015-04-09       Impact factor: 4.981

7.  PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions.

Authors:  X Wang; G Wang; Y Shi; L Sun; R Gorczynski; Y-J Li; Z Xu; D E Spaner
Journal:  Oncogenesis       Date:  2016-06-06       Impact factor: 7.485

8.  A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  H L Martin; R B Mounsey; K Sathe; S Mustafa; M C Nelson; R M Evans; P Teismann
Journal:  Neuroscience       Date:  2013-03-07       Impact factor: 3.708

9.  Limited Applicability of GW9662 to Elucidate PPARγ-Mediated Fatty Acid Effects in Primary Human T-Helper Cells.

Authors:  Anke Jaudszus; Stefan Lorkowski; Michael Gruen; Alexander Roth; Gerhard Jahreis
Journal:  Int J Inflam       Date:  2014-06-25

10.  Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation.

Authors:  Gwendoline Degueurce; Ilenia D'Errico; Christine Pich; Mark Ibberson; Frédéric Schütz; Alexandra Montagner; Marie Sgandurra; Lionel Mury; Paris Jafari; Akash Boda; Julien Meunier; Roger Rezzonico; Nicolò Costantino Brembilla; Daniel Hohl; Antonios Kolios; Günther Hofbauer; Ioannis Xenarios; Liliane Michalik
Journal:  EMBO Mol Med       Date:  2016-08-01       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.